CITIUS PHARMACEUTICALS INC (CTXR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.59-2.38%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CTXR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -85.4% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CTXR — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued
Dated 2026-08-21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 17, 2026, Citius Pharmaceuticals, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted our request for an extension through February 8, 2027 (the “Extension Notice”) to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”…
Why it matters: Going over this revenue level shows strong growth for LYMPHIR and supports growth plans.
Supportive ifQ3 revenue for LYMPHIR exceeds $2 million.
Worry ifQ3 revenue for LYMPHIR falls below $1.5 million.
Why it matters: Good global distribution helps more patients get LYMPHIR. It shows the company is growing.
Supportive ifCitius Oncology shares news of more LYMPHIR shipments to new global markets.
Worry ifNo new news on global shipments or problems with distribution.
Why it matters: M&A can drive growth and improve Citius's market position. Investors are keen on this.
Supportive ifAnnouncement of a new M&A deal that aligns with Citius's growth strategy.
Worry ifNo new M&A announcements or delays in current activities.
Why it matters: Fixing compliance issues is key for Citius. Delays can harm operations.
Worry ifA public update shows progress in fixing compliance issues.
Less concerning ifNo updates or more delays in fixing compliance issues.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$403 on $10,000 · ±4.0% | How much price usually moves either way. |
| Bad day | $977 loss on $10,000 · 9.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,359 loss on $10,000 · 73.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Successful M&A could enhance growth and improve financial performance. Investors will look for strategic moves.
Supportive ifA major deal or partnership news that benefits the business.
Worry ifNo new M&A activity or failed negotiations.
Why it matters: Fixing these issues is important for Citius. It affects how investors feel.
Worry ifManagement says they are making good progress on compliance issues.
Less concerning ifNo updates or more delays on compliance issues.
Why it matters: Better financial results may mean better management. Current losses are a concern.
Supportive ifA quarterly report shows smaller net losses than before.
Worry ifNet income continues to decline or worsens in the next quarter.
Why it matters: A big drop in cash reserves could hurt Citius's ability to fund operations and grow.
Worry ifCash and cash equivalents remain above $10 million.
Less concerning ifCash and cash equivalents drop below $10 million.
Why it matters: Getting financing will help operations and growth. This is very important.
Supportive ifCitius Oncology gets more financing. This is beyond the $36.5 million already announced.
Worry ifCitius Oncology does not get the expected financing. This affects its plans.
Why it matters: Continued growth in institutional orders shows demand for LYMPHIR is strong. This is key for revenue growth.
Supportive ifInstitutional vial orders rise by over 30% each quarter.
Worry ifInstitutional vial orders fall or grow less than 10% each quarter.
Why it matters: Following Nasdaq rules is key to keeping the listing and investor trust.
Worry ifCitius meets the $1.00 per share rule by February 2027.
Less concerning ifCitius fails to meet the $1.00 per share requirement by the deadline.
Why it matters: Good Phase 1 results could help LYMPHIR in combination therapies and grow its market.
Watch forPhase 1 trial data shows a response rate over 50% for LYMPHIR in combination therapies.
Also watch forPhase 1 trial data shows a response rate below 30% for LYMPHIR in combination therapies.